Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)
🎯 Key Takeaways
- Revenue grew 28.1% QoQ to ₹82 in Q1FY27.
- Market Cap
- ₹1,561
- P/E Ratio
- 34.9
- P/B Ratio
- 5.65
- ROE
- 16.5%
- ROCE
- 21.7%
- Debt/Equity
- 0.03
- Div Yield
- 1.69%
- Promoter
- 69.0%
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 74 | 73 | 64 | 82 |
| Operating Profit | 14 | 14 | 9 | 15 |
| OPM % | 18.9% | 19.0% | 13.8% | 18.4% |
| Net Profit | 13 | 11 | 9 | 13 |
| EPS | ₹1.88 | ₹1.67 | ₹1.25 | ₹2.00 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 |
| Reserves | 226 | 184 | 263 | 240 |
| Borrowings | 0 | 10 | 8 | 9 |
| Total Liabilities | 278 | 258 | 317 | 299 |
| Fixed Assets | 94 | 10 | 7 | 8 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 278 | 258 | 317 | 299 |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +55 |
| Investing | -45 |
| Financing | -12 |
| Net Cash Flow | -2 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 67.5% | 67.4% | 67.9% | 69.0% |
| FII | 2.1% | 2.1% | 2.4% | 2.3% |
| DII | 0.1% | 0.1% | 0.2% | 0.6% |
| Public | 21.1% | 21.2% | 20.7% | 19.3% |
| # Shareholders | 24,653 | 24,895 | 26,264 | 24,181 |
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.37 L Cr | 36.1 | 18.7% | — | 0.05 |
| DIVISLAB | 2.46 L Cr | 84.2 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.83 L Cr | 76.6 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | — | 0.43 |
| CIPLA | 1.09 L Cr | 32.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 97.8 | 20.8% | — | 0.45 |
| MANKIND | 1.03 L Cr | 50.6 | 13.9% | — | 0.38 |
| DRREDDY | 1.03 L Cr | 31.9 | 10.1% | — | 0.17 |
| AUROPHARMA | 95,887 | 26.0 | 12.8% | — | 0.20 |
| LUPIN | 93,367 | 16.5 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
📋 Recent Filings
- 🔴 Corporate Action2026-09-30Jagsonpal Pharmaceuticals announced the allotment of 1,01,825 equity shares of Rs. 2 each under its Employee Stock Option Plan 2022, increasing paid-u…
- Announcement2026-09-25Jagsonpal Pharmaceuticals has closed its insider trading window effective October 1, 2026, ahead of upcoming unaudited financial results for the quart…
- 🔴 Corporate Action2026-09-23Jagsonpal Pharmaceuticals announced on September 23, 2026, its agreement to acquire the Wellness Portfolio of Group Pharmaceuticals for an initial con…
- 🔴 Announcement2026-09-23Jagsonpal Pharmaceuticals announced on September 23, 2026, that it has entered into a Business Transfer Agreement to acquire the Wellness Portfolio of…
- 🟡 voting results2026-09-21Jagsonpal Pharmaceuticals held its 47th AGM on September 18, 2026 via video conferencing, with voting results filed on September 21, 2026. All five re…
- 🟡 Board Meeting2026-09-18Jagsonpal Pharmaceuticals held its 47th AGM on September 18, 2026 via video conference, electing Manish Gupta as chairperson after Harsha Raghavan's a…
- 🔴 annual report2026-08-27Jagsonpal Pharmaceuticals held its 47th AGM on September 18, 2026, approving FY26 results with revenue of ₹2,872.25 million and profit after tax of ₹4…
- 🟡 sustainability report2026-08-27Jagsonpal Pharmaceuticals Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 to BSE and NSE on August 27, 2…
- 🔴 annual report2026-08-27Jagsonpal Pharmaceuticals announced on August 27, 2026 that shareholders without registered email addresses received a letter providing a web-link and…
- 🔴 annual report2026-08-27Jagsonpal Pharmaceuticals reported 7% revenue growth to ₹287 crore and 19% PAT growth to ₹43 crore in FY26, with a ₹1,907 million cash position and ₹4…
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when JAGSNPHARM files new disclosures
Track JAGSNPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track JAGSNPHARM — FreeFree account · 2 AI queries/day